23andMe is exploring strategic alternatives, looking to raise capital

23andMe said it's started exploring strategic alternatives, including a possible sale.

New in the last 8 hours

OpenAI said to be in talks to raise $40B at a $340B valuation

Controversial genetics testing startup Nucleus Genomics raises $14M Series A 

New in the last 18 hours

Gaming M&A and financing deals grew 39% in 2024 | Drake Star

New in the last 48 hours

Meteomatics eyes U.S. expansion for its enterprise-focused weather forecasting tools